Nevada company sues Lilly for breach of contract over Alzheimer’s drug
Lilly called the lawsuit “baseless” and said PDL BioPharma “has no plausible claim to royalties” for donanemab, which is expected to be approved by the FDA this quarter.
Lilly called the lawsuit “baseless” and said PDL BioPharma “has no plausible claim to royalties” for donanemab, which is expected to be approved by the FDA this quarter.
RayzeBio is building a large factory on the northwest side of Indianapolis to make radioisotopes for cancer treatment.
Firms that normally try to sell drugs as soon as possible are suspending clinical trials and shifting timelines, while patient groups are demanding change.
Providers of the therapy say the new rates are not enough to keep them running and are far below the previous statewide average of $97 per hour.
Innovating in health care is not just hard and expensive—it is REALLY hard and expensive.
People who stopped taking Eli Lilly and Co.’s blockbuster drug Zepbound after about eight months regained half the weight they’d lost a year later, yet were significantly thinner than when they had started the obesity drug, according to a new study.
The Indianapolis-based nurses cite poor staffing ratios, patient care and wages as some of the driving reasons behind their efforts.
The Centers for Disease Control and Prevention also estimates that flu has caused as many as 55,000 hospitalizations and 4,600 deaths from Oct. 1 through Dec. 2.
The Biden administration is putting pharmaceutical companies on notice, warning them that if the price of certain drugs is too high, the government might cancel their patent protection and allow rivals to make their own versions.
The Court of Appeals of Indiana is considering a challenge to the state’s near total abortion ban on grounds it violates a religious freedom law.
The biggest U.S. drugstore chain aims to make the payment system more transparent by using a formula based on a drug’s cost, a fixed markup, and a fee that reflects the value of the pharmacy services, the company said Tuesday.
Dr. Leonard Dale Guyer has been the subject of controversy several times over the past two decades.
The company, Carmot Therapeutics, has numerous drugs under development. Its lead asset is a once-a-week injection that is in mid-stage development for the treatment of obesity.
The agreement hammered out with state and local governments and victims would provide billions of dollars to combat the opioid epidemic. The decision also has implications for other major product liability lawsuits settled through the bankruptcy system.
An estimated 130,000 Hoosiers over the age of 60 using Medicaid will receive notices in early 2024 advising them to choose a Managed Care Entity to coordinate their health coverage.
The move follows pushback by several neighborhood groups on the north side who expressed concern about the city’s plan, which could rely heavily on the Midtown tax-increment financing district to repay bonds issued for the acquisition.
Some warn that the spiraling number of deals could lead to large physician groups having an unfairly high market share, which could lead to price increases and cost-cutting.
The extension comes amid pushback from several investors, including Point’s largest institutional stock holder.
If trends continue, as many as 30 million people could end up being dropped from Medicaid. The numbers dwarf the Biden administration’s initial projections.
The business makes a hand-sanitizing device called Iggy that kills pathogens with ozone-infused water instead of soap or other chemicals.